Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-011 pembrolizumab + lenvatinib versus pembrolizumab + placebo in first-line advanced or metastatic urothelial carcinoma
2018-003752-21Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Pembrolizumab + lenvatinib with Pembrolizumab + placebo (2 arms). Primary endpoint: Progression-free survival. Started Feb 2019; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2018-003752-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003752-21.